Biblio
Export 2446 results:
Author Title Type [ Year] Filters: First Letter Of Keyword is A [Clear All Filters]
“Neuroprotective Effect of Phloretin in Rotenone-Induced Mice Model of Parkinson's Disease: Modulating mTOR-NRF2-p62 Mediated Autophagy-Oxidative Stress Crosstalk.”, J Alzheimers Dis, vol. 94, no. s1, pp. S109-S124, 2023.
, “Neuroprotective Properties of Eudesmin on a Cellular Model of Amyloid-β Peptide Toxicity.”, J Alzheimers Dis, vol. 94, no. s1, pp. S97-S108, 2023.
, “Neuroprotective Properties of Eudesmin on a Cellular Model of Amyloid-β Peptide Toxicity.”, J Alzheimers Dis, vol. 94, no. s1, pp. S97-S108, 2023.
, “Neuroprotective Properties of Eudesmin on a Cellular Model of Amyloid-β Peptide Toxicity.”, J Alzheimers Dis, vol. 94, no. s1, pp. S97-S108, 2023.
, “A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora.”, J Alzheimers Dis, vol. 94, no. s1, pp. S227-S239, 2023.
, “A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora.”, J Alzheimers Dis, vol. 94, no. s1, pp. S227-S239, 2023.
, “A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora.”, J Alzheimers Dis, vol. 94, no. s1, pp. S227-S239, 2023.
, “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.”, J Alzheimers Dis, vol. 94, no. 3, pp. 993-1004, 2023.
, “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.”, J Alzheimers Dis, vol. 94, no. 3, pp. 993-1004, 2023.
, “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.”, J Alzheimers Dis, vol. 94, no. 3, pp. 993-1004, 2023.
, “Odor Discrimination as a Marker of Early Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 3, pp. 1169-1178, 2023.
, “Pathogenesis, Animal Models, and Drug Discovery of Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 4, pp. 1265-1301, 2023.
, “Pathogenesis, Animal Models, and Drug Discovery of Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 4, pp. 1265-1301, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathological and Therapeutic Advances in Parkinson's Disease: Mitochondria in the Interplay.”, J Alzheimers Dis, vol. 94, no. s1, pp. S399-S428, 2023.
, “Pathological and Therapeutic Advances in Parkinson's Disease: Mitochondria in the Interplay.”, J Alzheimers Dis, vol. 94, no. s1, pp. S399-S428, 2023.
, “Phonological and Semantic Fluency in Alzheimer's Disease: A Systematic Review and Meta-Analysis.”, J Alzheimers Dis, vol. 95, no. 1, pp. 1-12, 2023.
, “The PI3K/AKT Signaling Pathway and Caspase-3 in Alzheimer's Disease: Which One Is the Beginner?”, J Alzheimers Dis, vol. 92, no. 2, pp. 391-393, 2023.
, “The PI3K/AKT Signaling Pathway and Caspase-3 in Alzheimer's Disease: Which One Is the Beginner?”, J Alzheimers Dis, vol. 92, no. 2, pp. 391-393, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis?”, J Alzheimers Dis, vol. 92, no. 3, pp. 799-801, 2023.
,